CRON

Cronos Group Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth 7/10
  • Value 2/10
Cronos Group sales and earnings growth
CRON Growth
Good
  • Revenue Y/Y 24.63%
  • EPS Y/Y -118.18%
  • FCF Y/Y -53.42%
Cronos Group gross and profit margin trends
CRON Profitability
Neutral
  • Gross margin 42.80%
  • EPS margin -6.40%
  • ROIC 5Y -20.56%
Cronos Group net debt vs free cash flow
CRON Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage -1.6

Cronos Group stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗